Evidence map›Paper›PMID 35628143›Full record

ArticleInternational journal of molecular sciences2022

Light-Control over Casein Kinase 1δ Activity with Photopharmacology: A Clear Case for Arylazopyrazole-Based Inhibitors.

Albert M Schulte, Dušan Kolarski, Vidya Sundaram, Ashutosh Srivastava, Florence Tama, Ben L Feringa, Wiktor Szymanski

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 3 countries.

Albert M SchulteStratingh Institute for Chemistry, University of Groningen, 9747 AG Groningen, The Netherlands.ORCID 0000-0001-9948-6132
Dušan KolarskiStratingh Institute for Chemistry, University of Groningen, 9747 AG Groningen, The Netherlands.ORCID 0000-0002-2077-3225
Vidya SundaramDiscipline of Biological Engineering, Indian Institute of Technology Gandhinagar, Gandhinagar 382355, India.
Ashutosh SrivastavaDiscipline of Biological Engineering, Indian Institute of Technology Gandhinagar, Gandhinagar 382355, India.ORCID 0000-0001-9820-720X
Florence TamaInstitute of Transformative BioMolecules (WPI-ITbM), Nagoya University, Chikusa, Nagoya 464-8601, Japan.ORCID 0000-0003-2021-5618
Ben L FeringaStratingh Institute for Chemistry, University of Groningen, 9747 AG Groningen, The Netherlands.
Wiktor SzymanskiStratingh Institute for Chemistry, University of Groningen, 9747 AG Groningen, The Netherlands.ORCID 0000-0002-9754-9248
University of Groningen · NLIndian Institute of Technology Gandhinagar · INRIKEN Center for Computational Science · JPUniversity Medical Center Groningen · NL

Funding

Dutch Research Council TOP GrantDutch Research Council VIDI Grant No. 723.014.001European Research Council Advanced Investigator Grant No. 227897Ramalingaswami Re-entry Fellowship GrantRoyal Netherlands Academy of Arts and Sciences GrantThe Netherlands Ministry of Education, Culture and Science Gravitation program 024.001.035
6 · The paper itself

Abstract

Protein kinases are responsible for healthy cellular processes and signalling pathways, and their dysfunction is the basis of many pathologies. There are numerous small molecule inhibitors of protein kinases that systemically regulate dysfunctional signalling processes. However, attaining selectivity in kinase inhibition within the complex human kinome is still a challenge that inspires unconventional approaches. One of those approaches is photopharmacology, which uses light-controlled bioactive molecules to selectively activate drugs only at the intended space and time, thereby avoiding side effects outside of the irradiated area. Still, in the context of kinase inhibition, photopharmacology has thus far been rather unsuccessful in providing light-controlled drugs. Here, we present the discovery and optimisation of a photoswitchable inhibitor of casein kinase 1δ (CK1δ), important for the control of cell differentiation, circadian rhythm, DNA repair, apoptosis, and numerous other signalling processes. Varying the position at which the light-responsive azobenzene moiety has been introduced into a known CK1δ inhibitor, LH846, revealed the preferred regioisomer for efficient photo-modulation of inhibitory activity, but the photoswitchable inhibitor suffered from sub-optimal (photo)chemical properties. Replacement of the bis-phenyl azobenzene group with the arylazopyrazole moiety yielded a superior photoswitch with very high photostationary state distributions, increased solubility and a 10-fold difference in activity between irradiated and thermally adapted samples. The reasons behind those findings are explored with molecular docking and molecular dynamics simulations. Results described here show how the evaluation of privileged molecular architecture, followed by the optimisation of the photoswitchable unit, is a valuable strategy for the challenging design of the photoswitchable kinase inhibitors.

Indexed as

Casein Kinase IdeltaProtein Kinase InhibitorsPyrazolesApoptosisHumansMolecular Docking SimulationCasein Kinase IdeltaProtein Kinase InhibitorsPyrazolesarylazopyrazole photoswitcheskinasesmolecular photoswitchesphotopharmacology

Identifiers

PMID35628143
PMCPMC9140716
OpenAlexW4280565274

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.